Loiseau P, Brachet-Liermain A, Legroux M, Jogeix M
Nouv Presse Med. 1977 Mar 12;6(10):813-7.
Phenobarbital and diphenylhydantoin were estimated in treated epileptics. An initial measurement was made in 457 patients. 96% were taking phenobarbital and 53% diphenylhydantoin. Only 37% of the phenobarbital levels and 18% of the diphenhlhydantoin levels were in a therapeutic range. Correlations between the levels, the stability of the epilepsy and signs of overdosage are discussed. Intolerance to phenobarbital reported in some patients, which appears to be real, is not reflected by "normal" or even low blood levels. By contrast, high levels of phenobarbital appear to be well tolerated. Signs of overdosage were quasi-constant when levels of diphenylhydantoin were greater than 15 mg/1. Doses of phenobarbital and of diphenylhydantoin were altered, levels assessed and the clinical condition evaluated in 134 patients. Bringing levels to within the therapeutic range resulted in the disappearance of attacks in 55% of cases for phenobarbital and 30% for diphenylhydantoin. Reduction of doses responsible for excessively high blood concentrations (overdosage) was practically never associated with an increase in the number of attacks. This adjustment is easy for phenobarbital though much more difficult for diphenylhydantoin. In this study, therapeutic levels were 15 to 25 mg/1 for phenobarbital, and 7 to 15 mg/1 for diphenylhydantoin.
对接受治疗的癫痫患者体内的苯巴比妥和苯妥英进行了测定。对457名患者进行了首次测量。96%的患者正在服用苯巴比妥,53%正在服用苯妥英。只有37%的苯巴比妥水平和18%的苯妥英水平处于治疗范围内。讨论了这些水平、癫痫稳定性和过量体征之间的相关性。一些患者报告的对苯巴比妥的不耐受似乎是真实存在的,但在“正常”甚至低血药浓度时并未体现出来。相比之下,高水平的苯巴比妥似乎耐受性良好。当苯妥英水平大于15毫克/升时,过量体征几乎是持续存在的。对134名患者改变了苯巴比妥和苯妥英的剂量,评估了血药浓度并评估了临床状况。将血药浓度调整到治疗范围内后,55%服用苯巴比妥的患者和30%服用苯妥英的患者发作消失。降低导致血药浓度过高(过量)的剂量实际上从未导致发作次数增加。这种调整对苯巴比妥来说很容易,而对苯妥英来说则困难得多。在本研究中,苯巴比妥的治疗浓度为15至25毫克/升,苯妥英为7至15毫克/升。